Speaker Bio
Dr. Beaulieu is the co-founder and Chief Scientific Officer at Peptomyc, a biotech company developing mini-protein therapeutics for cancer treatment.
PhD in Pharmacology with a focus on structural biology of proteins, Marie-Eve led the preclinical pharmaceutical development of OMO-103, the first direct MYC inhibitor to successfully complete a clinical trial showing safety and clinical activity in cancer patients in 2022. Marie-Eve helped design the company strategy, build the team and fundraise public >11MEur and private ~31MEur. She now leads Peptomyc’s pipeline expansion, biomarkers and the drug manufacturing activities.
Marie-Eve co-authored 8 patents, 30 peer-reviewed publications and 4 book chapters (ORCID 0000-0001-5224-8436). She was awarded competitive fellowships (incl. MITACS and FRSQ postdoc awards) and contributed to the company’s scientific and business excellence through local and international awards (eg. BioFit, Best company initiative at AJIEC, EIT Health Headstart, J&J StartUpSlam at BioEurope, and the highly competitive H2020 SME Instrument and EIC Accelerator).